Merck Inventory 2010-2024 | MRK
Merck inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
- Merck inventory for the quarter ending September 30, 2024 was $6.244B, a 1.84% increase year-over-year.
- Merck inventory for 2023 was $6.358B, a 7.56% increase from 2022.
- Merck inventory for 2022 was $5.911B, a 0.71% decline from 2021.
- Merck inventory for 2021 was $5.953B, a 7.18% increase from 2020.
Merck Annual Inventory
(Millions of US $) |
| 2023 |
$6,358 |
| 2022 |
$5,911 |
| 2021 |
$5,953 |
| 2020 |
$5,554 |
| 2019 |
$5,978 |
| 2018 |
$5,440 |
| 2017 |
$5,096 |
| 2016 |
$4,866 |
| 2015 |
$4,700 |
| 2014 |
$5,571 |
| 2013 |
$6,226 |
| 2012 |
$6,535 |
| 2011 |
$6,254 |
| 2010 |
$5,868 |
| 2009 |
$8,048 |
Merck Quarterly Inventory
(Millions of US $) |
| 2024-09-30 |
$6,244 |
| 2024-06-30 |
$6,469 |
| 2024-03-31 |
$6,510 |
| 2023-12-31 |
$6,358 |
| 2023-09-30 |
$6,131 |
| 2023-06-30 |
$5,930 |
| 2023-03-31 |
$5,863 |
| 2022-12-31 |
$5,911 |
| 2022-09-30 |
$5,614 |
| 2022-06-30 |
$5,535 |
| 2022-03-31 |
$5,774 |
| 2021-12-31 |
$5,953 |
| 2021-09-30 |
$5,603 |
| 2021-06-30 |
$5,499 |
| 2021-03-31 |
$6,402 |
| 2020-12-31 |
$5,554 |
| 2020-09-30 |
$6,128 |
| 2020-06-30 |
$6,056 |
| 2020-03-31 |
$5,846 |
| 2019-12-31 |
$5,978 |
| 2019-09-30 |
$5,855 |
| 2019-06-30 |
$5,847 |
| 2019-03-31 |
$5,712 |
| 2018-12-31 |
$5,440 |
| 2018-09-30 |
$5,416 |
| 2018-06-30 |
$5,178 |
| 2018-03-31 |
$5,382 |
| 2017-12-31 |
$5,096 |
| 2017-09-30 |
$5,263 |
| 2017-06-30 |
$5,407 |
| 2017-03-31 |
$5,146 |
| 2016-12-31 |
$4,866 |
| 2016-09-30 |
$5,244 |
| 2016-06-30 |
$5,248 |
| 2016-03-31 |
$5,102 |
| 2015-12-31 |
$4,700 |
| 2015-09-30 |
$5,123 |
| 2015-06-30 |
$5,306 |
| 2015-03-31 |
$5,539 |
| 2014-12-31 |
$5,571 |
| 2014-09-30 |
$5,819 |
| 2014-06-30 |
$6,136 |
| 2014-03-31 |
$6,376 |
| 2013-12-31 |
$6,226 |
| 2013-09-30 |
$6,741 |
| 2013-06-30 |
$6,766 |
| 2013-03-31 |
$6,773 |
| 2012-12-31 |
$6,535 |
| 2012-09-30 |
$6,731 |
| 2012-06-30 |
$6,249 |
| 2012-03-31 |
$6,339 |
| 2011-12-31 |
$6,254 |
| 2011-09-30 |
$6,239 |
| 2011-06-30 |
$6,225 |
| 2011-03-31 |
$6,057 |
| 2010-12-31 |
$5,868 |
| 2010-09-30 |
$6,264 |
| 2010-06-30 |
$6,244 |
| 2010-03-31 |
$6,825 |
| 2009-12-31 |
$8,048 |
| 2009-09-30 |
$2,096 |
| 2009-06-30 |
$2,155 |
| 2009-03-31 |
$2,128 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$260.350B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
